Stay updated on Tavo in TNBC Clinical Trial
Sign up to get notified when there's something new on the Tavo in TNBC Clinical Trial page.

Latest updates to the Tavo in TNBC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe record describes a Phase 2 study of tavokinogene telseplasmid with pembrolizumab, with or without chemotherapy, for patients with advanced or metastatic triple-negative breast cancer. It also provides eligibility requirements, participating locations, and study outcomes.SummaryDifference72%

- Check16 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide banner announces an NIH transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe ClinicalTrials.gov 403 error page shows a newer site revision number in its footer.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the study details, blocking access to the record. This indicates an access restriction or server issue that prevents viewing the trial information on this page.SummaryDifference21%

Stay in the know with updates to Tavo in TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tavo in TNBC Clinical Trial page.